Skip to content

Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03177408
Enrollment
100
Registered
2017-06-06
Start date
2017-08-15
Completion date
2017-12-31
Last updated
2017-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diastolic Dysfunction, Hypertension, Inflammation

Keywords

Diastolic Dysfunction, Hypertension, HMGB1

Brief summary

This study evaluated the association between HMGB1 and diastolic dysfunction in hypertensive patients. HMGB1 level were tested in all patients, and diastolic function determined by echocardiographic.

Interventions

None listed

Sponsors

Jing Li
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

All of the hypertensive patients in both diastolic dysfunction and control groups were either newly diagnosed or were aware of hypertension without using any pharmacotherapy. \-

Exclusion criteria

Individuals already under treatment for hypertension were not include. \-

Design outcomes

Primary

MeasureTime frameDescription
Differences of HMGB1 levels between hypertensive patients with and without diastolic dysfunctionon the day of admissionBlood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.

Secondary

MeasureTime frameDescription
Differences of HMGB1 levels between grades of diastolic dysfunctionon the day of admissionBlood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026